GSK says HIV shot is better than daily pills for some patients

GSK has made a major push into long-acting HIV drugs as it works to soften the blow from the loss of exclusivity of its blockbuster drug dolutegravir, which is set to face competition in the US in 2028 and in Europe by 2029.

The drug, called Cabenuva, is injected as two shots every four weeks.

GSK's long-acting HIV drug worked better than daily pills for some patients, especially those who have trouble adhering to a treatment schedule, according to a unit of the UK pharmaceutical company.

The positive interim results from an ongoing trial have resulted in all patients in the study being offered the long-acting injectable drug, said ViiV Healthcare, which specialises in HIV treatments and is majority owned by GSK. The drug, called Cabenuva, is injected as two shots every four weeks. It was approved in the US in 2021.